NCI Grants Lysin Exclusive Rights to Mesothelin Cancer Immunotoxins
Published Date: 9/10/2025
Notice
Summary
The National Cancer Institute is planning to give Lysin Therapeutics an exclusive license to use their special anti-mesothelin immunotoxins to treat cancers that have mesothelin. This means Lysin can develop and sell new cancer treatments, potentially helping patients with tough-to-treat tumors. The deal could speed up new medicines and impact cancer care soon, with business and health benefits on the horizon.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
NCI plans exclusive license to Lysin
The National Cancer Institute (NCI) is contemplating granting an NCI Exclusive Patent License to Lysin Therapeutics, Inc., a company located in Silver Spring, MD, to practice inventions embodied in the patents listed in the notice's Supplementary Information. This gives Lysin the legal right to develop and commercialize the patented anti-mesothelin immunotoxin inventions listed in that supplement.
Potential new treatments for mesothelin cancers
The license under consideration covers anti-mesothelin immunotoxins for treating mesothelin-expressing cancers. If granted, the license would allow Lysin Therapeutics to develop and sell treatments that use these patented anti-mesothelin immunotoxins for cancers that express mesothelin.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20365, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings on October 29-30, 2026, to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like biochemistry, software engineering, and mental health will be affected, with no direct money changes announced but important decisions coming soon.
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19718, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding two closed virtual meetings in October 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research teams applying for grants should note these dates as they impact funding decisions but don’t involve public attendance.
2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)
The NIH is asking for approval to keep collecting info from citizen science and crowdsourcing projects, making it easier to gather public input on health research. This affects anyone involved in these projects and invites comments by October 28, 2026. No new costs or big changes, just a smooth way to keep the data flowing for better science!
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
2026-19706, Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
The NIH wants to make it easier for people who join clinical studies to get simple summaries of the study results. This new policy aims to boost trust and teamwork between researchers and participants, helping science move faster and better. They’re asking for your thoughts by October 26, 2026, so get ready to share your ideas!
Previous / Next Documents
Previous: 2025-17378, Notice of Lodging of Proposed Second Material Modification to Consent Decree Under Title VI of the Clean Air Act
The Department of Justice is updating a deal with Trident Seafoods to fix problems with their old, leaky refrigeration systems that harm the ozone layer. They’re giving Trident four more years to meet one deadline but also making them upgrade one big fridge early and do extra leak checks. People have 30 days to share their thoughts on these changes before they’re final.
Next: 2025-17380, Charter Amendments, Establishments, Reestablishments, Renewals, and Terminations; Novel and Exceptional Technology and Research Advisory Committee
The NIH is renewing the Novel and Exceptional Technology and Research Advisory Committee to keep advising on cool new biomedical tech. They’re holding a virtual meeting on September 29, 2025, to discuss public involvement in clinical research. This keeps important research moving forward with fresh ideas and public input, all without extra costs to taxpayers.